Modified polynucleotides encoding apoptosis inducing factor 1
First Claim
Patent Images
1. An mRNA encoding amino acid 353 to 613 of SEQ ID NO:
- 4868, wherein said mRNA comprises a coding region, said coding region having at least 80% identity to SEQ ID NO;
32141.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
-
Citations
17 Claims
-
1. An mRNA encoding amino acid 353 to 613 of SEQ ID NO:
- 4868, wherein said mRNA comprises a coding region, said coding region having at least 80% identity to SEQ ID NO;
32141. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
2. The mRNA of claim 1, wherein the mRNA comprises at least one untranslated region 5′
- relative to the coding region and at least one untranslated region 3′
relative to the coding region.
- relative to the coding region and at least one untranslated region 3′
-
3. The mRNA of claim 2, wherein the 5′
- untranslated region is heterologous to the coding region of the mRNA.
-
4. The mRNA of claim 2, wherein the 3′
- untranslated region is heterologous to the coding region of the mRNA.
-
5. The mRNA of claim 2, wherein the 5′
- untranslated region and the 3′
untranslated region are heterologous to the coding region of the mRNA.
- untranslated region and the 3′
-
6. The mRNA of claim 2, wherein the mRNA comprises at least two stop codons.
-
7. The mRNA of claim 1, wherein the coding region is selected from the group consisting of SEQ ID NO:
- 32141 and 32158.
-
8. The mRNA of claim 1, wherein the coding region is at least 99% identical to SEQ ID NO:
- 32141.
-
9. The mRNA of claim 1, wherein the coding region consists of SEQ ID NO:
- 32141.
-
10. A pharmaceutical composition comprising the mRNA of claim 1 and a pharmaceutically acceptable excipient.
-
11. The pharmaceutical composition of claim 10 wherein the pharmaceutically acceptable excipient is selected from a solvent, aqueous solvent, non-aqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid, lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplex, peptide, protein, cell, hyaluronidase, and mixtures thereof.
-
12. A method of producing a protein of interest in a cell, tissue or organism comprising contacting said cell, tissue or organism with the mRNA of claim 1.
-
13. The method of claim 12, wherein the mRNA comprises at least one untranslated region 5′
- relative to the coding region and at least one untranslated region 3′
relative to the coding region.
- relative to the coding region and at least one untranslated region 3′
-
14. The method of claim 13, wherein the 5′
- untranslated region is heterologous to the coding region of the mRNA.
-
15. The method of claim 13, wherein the 3′
- untranslated region is heterologous to the coding region of the mRNA.
-
16. The method of claim 13, wherein the 5′
- untranslated region and the 3′
untranslated region are heterologous to the coding region of the mRNA.
- untranslated region and the 3′
-
17. The method of claim 13, wherein the mRNA comprises at least two stop codons.
-
2. The mRNA of claim 1, wherein the mRNA comprises at least one untranslated region 5′
- 4868, wherein said mRNA comprises a coding region, said coding region having at least 80% identity to SEQ ID NO;
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeModerna TX, Inc. (Moderna, Inc.)
-
Original AssigneeModerna Therapeutics, Inc. (Moderna, Inc.)
-
InventorsChakraborty, Tirtha, de Fougerolles, Antonin
-
Primary Examiner(s)Gussow, Anne
-
Assistant Examiner(s)GALISTEO GONZALEZ, ANTONIO
-
Application NumberUS14/106,988Publication NumberTime in Patent Office841 DaysField of SearchNoneUS Class Current1/1CPC Class CodesA61K 31/7115 Nucleic acids or oligonucle...A61K 38/00 Medicinal preparations cont...A61K 38/17 from animals; from humans e...A61K 38/177 Receptors; Cell surface ant...A61K 38/1816 Erythropoietin [EPO]A61K 38/1891 Angiogenesic factors; Angio...A61K 38/191 Tumor necrosis factors [TNF...A61K 38/193 Colony stimulating factors ...A61K 38/212 IFN-alphaA61K 38/45 Transferases (2)A61K 38/4846 Factor VII (3.4.21.21); Fac...A61K 47/543 Lipids, e.g. triglycerides;...A61K 48/0033 the non-active part being n...A61K 48/0041 the non-active part being p...A61K 48/005 characterised by an aspect ...A61K 48/0066 Manipulation of the nucleic...A61K 48/0075 characterised by an aspect ...A61K 9/0019 Injectable compositions; In...A61K 9/1271 Non-conventional liposomes,...A61K 9/145 with organic compoundsA61K 9/5123 : Organic compounds, e.g. fat...A61K 9/5146 : obtained otherwise than by ...A61K 9/5153 : Polyesters, e.g. poly(lacti...A61P 1/00 : Drugs for disorders of the ...A61P 1/04 : for ulcers, gastritis or re...A61P 11/00 : Drugs for disorders of the ...A61P 13/00 : Drugs for disorders of the ...A61P 13/12 : of the kidneysA61P 15/00 : Drugs for genital or sexual...A61P 17/00 : Drugs for dermatological di...A61P 17/02 : for treating wounds, ulcers...A61P 17/04 : AntipruriticsA61P 17/06 : AntipsoriaticsA61P 17/08 : AntiseborrheicsA61P 17/14 : for baldness or alopeciaA61P 19/00 : Drugs for skeletal disordersA61P 19/02 : for joint disorders, e.g. a...A61P 19/10 : for osteoporosisA61P 21/00 : Drugs for disorders of the ...A61P 21/04 : for myasthenia gravisA61P 25/00 : Drugs for disorders of the ...A61P 25/02 : for peripheral neuropathiesA61P 25/14 : for treating abnormal movem...A61P 25/18 : Antipsychotics, i.e. neurol...A61P 25/24 : AntidepressantsA61P 25/28 : for treating neurodegenerat...A61P 25/30 : for treating abuse or depen...A61P 27/02 : Ophthalmic agentsA61P 29/00 : Non-central analgesic, anti...A61P 3/00 : Drugs for disorders of the ...A61P 3/06 : AntihyperlipidemicsA61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/10 : AntimycoticsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/18 : for HIVA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 35/04 : specific for metastasisA61P 37/00 : Drugs for immunological or ...A61P 37/02 : ImmunomodulatorsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 7/04 : Antihaemorrhagics; Procoagu...A61P 7/06 : AntianaemicsA61P 9/00 : Drugs for disorders of the ...A61P 9/10 : for treating ischaemic or a...C07H 21/02 : with ribosyl as saccharide ...C07K 14/005 : from virusesC07K 14/435 : from animals; from humansC07K 14/43595 : from coelenteratae, e.g. me...C07K 14/47 : from mammalsC07K 14/4705 : stimulating, promoting or a...C07K 14/4713 : Autoimmune diseases, e.g. I...C07K 14/4723 : Cationic antimicrobial pept...C07K 14/4746 : p53C07K 14/475 : Growth factors; Growth regu...C07K 14/485 : Epidermal growth factor [EG...C07K 14/495 : Transforming growth factor ...C07K 14/505 : Erythropoietin [EPO]C07K 14/515 : Angiogenesic factors; Angio...C07K 14/525 : Tumour necrosis factor [TNF]C07K 14/535 : Granulocyte CSF; Granulocyt...C07K 14/5418 : IL-7C07K 14/56 : IFN-alphaC07K 14/61 : Growth hormone [GH], i.e. s...C07K 14/62 : InsulinsC07K 14/705 : Receptors; Cell surface ant...C07K 14/745 : Blood coagulation or fibrin...C07K 16/00 : Immunoglobulins [IGs], e.g....C07K 16/2863 : against receptors for growt...C07K 16/2887 : against CD20C07K 16/40 : against enzymesC12N 15/11 : DNA or RNA fragments; Modif...C12N 15/52 : Genes encoding for enzymes ...C12N 15/85 : for animal cellsC12N 15/87 : Introduction of foreign gen...C12N 15/88 : using microencapsulation, e...C12N 9/0069 : acting on single donors wit...C12N 9/0091 : oxidizing metal ions (1.16)C12N 9/1051 : Hexosyltransferases (2.4.1)C12N 9/1241 : Nucleotidyltransferases (2....C12N 9/16 : acting on ester bonds (3.1)C12N 9/2402 : hydrolysing O- and S- glyco...C12N 9/2445 : Beta-glucosidase (3.2.1.21)C12N 9/6435 : Plasmin (3.4.21.7), i.e. fi...C12N 9/6437 : Coagulation factor VIIa (3....C12N 9/644 : Coagulation factor IXa (3.4...C12N 9/6443 : Coagulation factor XIa (3.4...C12N 9/6451 : Coagulation factor XIIa (3....C12N 9/88 : Lyases (4.)C12N 9/93 : Ligases (6)C12P 13/04 : Alpha- or beta- amino acids...C12P 21/00 : Preparation of peptides or ...C12P 21/005 : Glycopeptides, glycoproteinsC12Y 113/12007 : Photinus-luciferin 4-monoox...C12Y 116/03001 : Ferroxidase (1.16.3.1), i.e...C12Y 207/07012 : UDP-glucose--hexose-1-phosp...C12Y 304/21007 : Plasmin (3.4.21.7), i.e. fi...C12Y 304/21022 : Coagulation factor IXa (3.4...C12Y 304/21027 : Coagulation factor XIa (3.4...C12Y 403/02001 : Argininosuccinate lyase (4....C12Y 603/02019 : Ubiquitin-protein ligase (6...Y02A 50/30 : Against vector-borne diseas...